advertisement
Eye 157
Showing records 1 to 25 | Display all abstracts in Eye106751 Preserflo microshunt implant for the treatment of refractory uveitic glaucoma: 36-month outcomes
Triolo G
Eye 2023; 37: 2535-2541
106663 Approaching rehabilitation in patients with advanced glaucoma
Deemer AD
Eye 2023; 37: 1993-2006
106475 A simple surgical solution for the treatment of persistent postoperative hypotony after PRESERFLO MicroShunt implantation
Aguilar-Munoa S
Eye 2023; 37: 2126-2129
105231 Can the long term using of pregabalin in fibromyalgia affect the choroid and retinal nerve fiber layer?
Biçer GY
Eye 2022; 36: 2318-2322
105716 Diagnostic accuracy of an iPad application for detection of visual field defects
Richardson QR
Eye 2023; 37: 1690-1695
106559 Binocular visual field in adults with horizontal strabismus and driving requirements
Alfaqawi F
Eye 2023; 37: 2220-2225
105745 Regional variation in the incidence of pseudo-exfoliation in the Andhra Pradesh Eye Disease Study (APEDS)
Choudhari NS
Eye 2023; 37: 1704-1710
105873 Feasibility, efficacy and safety of early lens extraction in patients with pseudoexfoliation glaucoma: a feasibility and pilot study
Pose-Bazarra S
Eye 2022; 0: 1-7
106579 Association of topical glaucoma medications with lacrimal drainage obstruction and eyelid malposition
Quinn MP
Eye 2023; 37: 2233-2239
105202 Endocyclophotocoagulation combined with phacoemulsification in surgically naive primary open-angle glaucoma: three-year results
Yap TE
Eye 2022; 36: 1890-1895
106588 Will the PRESERFLO™ MicroShunt impact the future of trabeculectomy practice? A UK and Éire Glaucoma Society National Survey
Kuet ML
Eye 2022; 0: 1-5
106083 Systematic review of the method and quality of reporting of complications from studies evaluating innovative glaucoma surgical procedures
Bonnar J
Eye 2023; 37: 1774-1777
106738 Childhood blindness incidence and aetiologies trends in Israel 2014-2020: what should we focus on?
Israeli A
Eye 2022; 0: 1-6
106259 Incidence and risk factors for glaucoma development and progression after corneal transplantation
Saini C
Eye 2023; 37: 2117-2125
106579 Association of topical glaucoma medications with lacrimal drainage obstruction and eyelid malposition
Quinn MP
Eye 2023; 37: 2233-2239
105803 Geographic and socioeconomic access disparities to Phase 3 clinical trials in ophthalmology in the United States
Soares RR
Eye 2023; 37: 1822-1828
106344 Association between atrial fibrillation and the risk of glaucoma development: a 12-year Nationwide cohort study
Cho HK
Eye 2023; 37: 2033-2041
106258 UK Biobank retinal imaging grading: methodology, baseline characteristics and findings for common ocular diseases
Warwick AN
Eye 2023; 37: 2109-2116
105983 Adherence to topical glaucoma therapy in patients attending virtual clinics
Cheng KKW
Eye 2023; 37: 1922-1927
106697 A novel heterozygous c.733 T > G MYOC mutation associated with juvenile-onset open-angle glaucoma in a Chinese family
Dai A
Eye 2023; 37: 2488-2493
105767 Determinants of late presentation of glaucoma in Hong Kong
Lai ACK
Eye 2023; 37: 1717-1724
106636 Cost-effectiveness of polygenic risk profiling for primary open-angle glaucoma in the United Kingdom and Australia
Liu Q
Eye 2023; 37: 2335-2343
105716 Diagnostic accuracy of an iPad application for detection of visual field defects
Richardson QR
Eye 2023; 37: 1690-1695
105227 Ankle-brachial index and ocular diseases in a Russian population
Bikbov MM
Eye 2022; 36: 2294-2303
106579 Association of topical glaucoma medications with lacrimal drainage obstruction and eyelid malposition
Kratky V
Eye 2023; 37: 2233-2239
